Dr. Vivek Mohan discusses Lumbar Spine Fusion with one of his former patients.

Disclosure:

Mohan, Vivek: Consulting: AIM Specialty Health (B), Baxter (B), Seaspine (C); Speaking and/or Teaching Arrangements: Providence Medical (B).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Featuring: Christopher M. Bono, MD, F. Todd Wetzel, MD, William C. Watters, MD, MS

Disclosures:

Bono, Christopher M.: Royalties: Wolters Kluwer (A), Elsevier (B); Consulting: United Health Care (B); Other Office: The Spine Journal (D); Fellowship Support: OMEGA (D, Paid directly to institution/employer).

Watters, William C.: Board of Directors: American Board Of Spine Surgery (None); Consulting: Interqual (B), Intrinsic Therapeutics (A), MCG Health (None).

Wetzel, F. Todd: Stock Ownership: Relievant Medical (less than 1%).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

[1 of 12]

Hear Section on Intraoperative Neurophysiological Monitoring (IONM) Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, “What information is critical to communicate to the IONM team and how far in advance of surgery?”

It’s not uncommon for the IONM team to learn the details of the surgical procedure after incision, as it unfolds. This poses a number of problems. The IONM team needs to know detailed surgical plan, diagnosis and patient insurance information at least 48-hours in advance for non-emergent surgery. This will make IONM less likely to fail because the IONM team can make sure the correct equipment/electrodes/people are in the room, and the correct tests are being run with optimized anesthesia. This will also limit common issues with insurance. 

Disclosures:

Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D).

Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Faisel Zaman, MD, Chair of the Patient Education Committee, discusses acute back pain.

Disclosure:

Zaman, Faisel M.: Nothing to Disclose

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Faisel Zaman, MD, Chair of the Patient Education Committee, discusses causes and treatments for degenerative disc disease.

Disclosure:

Zaman, Faisel M.: Nothing to Disclose

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Douglas Pahl, MD (Public Affairs Committee Chair), William Sullivan, MD (SpineLine Medical Editor) and Andrew Pugely, MD (Author) discuss the Value in Spine Care article, "Physician and Hospital Reputation Management: How to Navigate the Quagmire of Public Quality Rankings, Patient Satisfaction and Online Review," which was published in the March/April 2018 issue of NASS' SpineLine magazine.

Access the article here. 

Disclosures:

Pahl, Douglas W.: Stock Ownership: Nanovis (14,837 Shares, Paid directly to institution/employer), Trainer Rx (less than 1%), Vertera (D, Paid directly to institution/employer); Trips/Travel: Medtronic (Nonfinancial, Outside 12-Month Requirement).

Pugely, Andrew J.: Royalties: Globus Medical (A); Consulting: Globus Medical (B); Other: AAOS (Nonfinancial, Coding Committee).

Sullivan, William J.: Board of Directors: NASS (Board of Directors, Executive Committee); Trips/Travel: NASS (B).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Chad Patton, MD (Public Affairs Committee Chair), William Sullivan, MD (SpineLine Medical Editor) and Emily Miller, MD (Review Author) discuss the Invited Review article on "Risk Stratification and the Future of Spine Surgery," which was published in the January/February 2018 issue of NASS' SpineLine magazine.

Access the article here.

Disclosures:

Patton, Chad M.: Speaking and/or Teaching Arrangements: Baxter (B), Medtronic (B); Stock Ownership: Physiciancy Medical Scribes (<1%).

Sullivan, William J.: Board of Directors: NASS (Board of Directors, Executive Committee); Trips/Travel: NASS (B).

Miller, Emily: Nothing to Disclose

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Saralyn Mark, MD (iGIANT, Yale University, Georgetown University), Kimberly J. Templeton, MD (University of Kansas) and Gregory Whitcomb, DC (Medical College of Wisconsin) discuss women’s issues in spine care.

Disclosures:

Mark, Saralyn: Nothing to Disclose

Templeton, Kimberly J.: Nothing to Disclose 

Whitcomb, Gregory L.: Nothing to Disclose 

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Sigurd Berven, MD (University of California San Francisco) and Michael Y. Wang, MD, FACS (The University of Miami) discuss the practice of and future of pedicle subtraction osteotomies.

Disclosures:

Berven, Sigurd H.: Consulting: Innovasis (B), Medicrea (C), Medtronic (C); Fellowship Support: Globus Medical (D); Grants: AO Spine (E, Paid directly to institution/employer), Globus (D, Paid directly to institution/employer); Private Investments: Green Sun Medical (50,000 Shares); Royalties: Stryker (F); Scientific Advisory Board: Globus Medical (Stock options); Speaking and/or Teaching Arrangements: Medtronic (B), Stryker Spine (B); Stock Ownership: Globus Medical (25,000 Shares), Providence Medical (2,500 Shares); Trips/Travel: Scoliosis Research Society (Travel Expense Reimbursement, Paid directly to institution/employer).

Wang, Michael Y.: Royalties: DePuy Synthes Spine (F); Stock Ownership: ISD (<1%), Medical Device Partners (<1%); Consulting: Stryker (C), Spineology (C), K2M (C), DePuy Synthes (C); Scientific Advisory Board: Vallum (A).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Daniel Resnick, MS, MD (Madison, WI), Eeric Truumees, MD (Austin, TX), Zoher Ghogawala, MD (Boston, MA) and Jeffrey Wang, MD (Los Angeles, CA) discuss the trends in treatment of degenerative spondylolisthesis.

Disclosures:

Ghogawala, Zoher: Board of Directors: Cervical Spine Research Society (Nonfinancial, Research Committee Chair, Registry Director), GN2.0-Nidus (66%), Joint Spine Section - AANS-CNS (Nonfinancial, Chair).

Resnick, Daniel K.: Scientific Advisory Board: NIDUS (None).

Truumees, Eeric: Board of Directors: Seton Family of Doctors (No additional pay, part of base compensation); Other Office: AAOS Communications Cabinet (E); Research Support (Staff and/or materials): Dova Pharmaceuticals (A, Paid directly to institution/employer), Medtronic (C, Paid directly to institution/employer), Pfizer (E, Paid directly to institution/employer), Relievant (F, Paid directly to institution/employer), Stryker Spine (B, Paid directly to institution/employer), Vertex Pharma (D, Study cancelled, Outside 12-Month Requirement, Paid directly to institution/employer); Trips/Travel: AAOS (Travel Reimbursement).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+